Should persons with acute myeloid leukemia (AML) in 1st histological complete remission who are measurable residual disease (MRD) test positive receive an allotransplant?

Leukemia. 2020 Apr;34(4):963-965. doi: 10.1038/s41375-020-0780-6. Epub 2020 Mar 4.
No abstract available

Publication types

  • Review

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Child
  • Clinical Decision-Making / ethics*
  • Graft Survival
  • Graft vs Host Disease / diagnosis
  • Graft vs Host Disease / immunology
  • Graft vs Host Disease / mortality
  • Graft vs Host Disease / pathology*
  • Hematopoietic Stem Cell Transplantation / ethics*
  • Hematopoietic Stem Cell Transplantation / methods
  • Hematopoietic Stem Cell Transplantation / mortality
  • Humans
  • Leukemia, Myeloid, Acute / immunology
  • Leukemia, Myeloid, Acute / mortality
  • Leukemia, Myeloid, Acute / pathology
  • Leukemia, Myeloid, Acute / therapy*
  • Myeloablative Agonists / therapeutic use
  • Neoplasm, Residual
  • Recurrence
  • Remission Induction
  • Survival Analysis
  • Transplantation Conditioning / methods
  • Transplantation, Homologous

Substances

  • Myeloablative Agonists